U01 Research Project – Cooperative Agreements
Funding Opportunity Announcement (FOA) Numbers: RFA-AI-19-059
The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage malaria vaccines, including sporozoite-based vaccines. Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit performance superior to currently available sporozoite-based vaccines and are suitable for further downstream process development and future clinical evaluation.
Eligibility
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Award Budget
The application budget may not exceed $750K in direct costs per year and should reflect the actual needs of the project.
Award Project Period
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Key Dates
Open Date (Earliest Submission Date): December 17, 2019
Letter of Intent Due Date(s): December 17, 2019
*Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Expiration Date: January 18, 2020
Application Due Date(s)
January 17, 2020
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Full details: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-059.html
